R&D
Developing innovative therapeutics based on next-generation mRNA·LNP platform technology.
Platform Technology
SML Biopharm possesses an mRNA platform with optimized UTR and poly(A) tail for enhanced stability and expression efficiency. While advancing next-generation mRNA platforms and new drug pipelines, we are independently developing lipid nanoparticles (LNP) for efficient delivery, leading effective R&D and rapid research progress.
Immunotherapy
Induces immune response and treatment by expressing specific antigens through mRNA. Various new drug development including prophylactic vaccines and cancer vaccines is possible.
In vivo Protein Therapeutics
Expresses specific peptides or proteins (antibodies, enzymes, etc.) for disease treatment. Target protein production is much simpler and more efficient, and can be applied to various diseases including infectious diseases, cancer, genetic diseases, and rare diseases.
Pipeline
We are developing innovative therapeutics for various diseases based on mRNA platform technology.
Development Process
We develop innovative therapeutics through systematic R&D processes.
Discovery
Target discovery and<br>candidate exploration
Preclinical
Preclinical testing and<br>efficacy/safety validation
Clinical Trial
Clinical trials<br>(Phase 1-3)
Regulatory
Regulatory submission<br>and approval
Commercialization
Commercialization and<br>market launch
Patents & Publications
We secure innovative technologies through continuous R&D.
SFTS Virus Neutralizing Antibody Sequence
Research Collaboration
SML Biopharm accelerates innovative therapeutic development<br>through collaboration with domestic and international research institutions and companies.